Franklin Biotechnology Discovery Fund Price To Earning
| FRBRX Fund | USD 150.75 0.48 0.32% |
Franklin Biotechnology Discovery fundamentals help investors to digest information that contributes to Franklin Biotechnology's financial success or failures. It also enables traders to predict the movement of FRANKLIN Mutual Fund. The fundamental analysis module provides a way to measure Franklin Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Franklin Biotechnology mutual fund.
FRANKLIN |
Franklin Biotechnology Discovery Mutual Fund Price To Earning Analysis
Franklin Biotechnology's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Franklin Biotechnology Price To Earning | 19.51 X |
Most of Franklin Biotechnology's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Franklin Biotechnology Discovery is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Franklin Biotechnology Discovery has a Price To Earning of 19.51 times. This is 151.09% higher than that of the Franklin Templeton Investments family and significantly higher than that of the Health category. The price to earning for all United States funds is notably lower than that of the firm.
FRANKLIN Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Franklin Biotechnology's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the mutual funds which would be a good addition to a portfolio. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics of similar companies.Franklin Biotechnology is currently under evaluation in price to earning among similar funds.
Fund Asset Allocation for Franklin Biotechnology
The fund consists of 98.75% investments in stocks, with the rest of investments allocated between different money market instruments and various exotic instruments.Asset allocation divides Franklin Biotechnology's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
FRANKLIN Fundamentals
| Price To Earning | 19.51 X | ||||
| Price To Book | 4.46 X | ||||
| Price To Sales | 6.21 X | ||||
| Total Asset | 833.93 M | ||||
| Year To Date Return | 9.54 % | ||||
| One Year Return | 34.08 % | ||||
| Three Year Return | 4.14 % | ||||
| Five Year Return | 5.56 % | ||||
| Ten Year Return | 17.44 % | ||||
| Net Asset | 1.42 B | ||||
| Cash Position Weight | 1.04 % | ||||
| Equity Positions Weight | 98.75 % |
About Franklin Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Franklin Biotechnology Discovery's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology Discovery based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in FRANKLIN Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether FRANKLIN Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in FRANKLIN with respect to the benefits of owning Franklin Biotechnology security.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |